Intercell AG (VSE: ICLL) declared that its traitor Merck & Co., Inc. has initiated a Phase II clinical effort of V710, an investigational immunogen for the hindrance of Staphylococcus aureus (S. aureus) infections. This irregular threefold blind, placebo dominated think aims to appraise the country and immunogenicity of the immunogen politician in patients with end-stage kidney disease on hemodialysis.

Tags: Initiation, Led